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SUMMARY 
 
Tissue regeneration requires inflammatory and reparatory activity of macrophages. 
Macrophages detect and eliminate the damaged tissue and subsequently promote 
regeneration. This dichotomy requires the switch of effector functions of macrophages 
coordinated with other cell types inside the injured tissue. The gene regulatory events 
supporting the sensory and effector functions of macrophages involved in tissue repair 
are not well understood. Here we show that the lipid activated transcription factor, 
PPARγ is required for proper skeletal muscle regeneration, acting in repair macrophages. 
PPARγ controls the expression of the transforming growth factor- (TGF- family 
member, GDF3, which in turn regulates the restoration of skeletal muscle integrity by 
promoting muscle progenitor cell fusion. This work establishes PPARγ as a required 
metabolic sensor and transcriptional regulator of repair macrophages. Moreover, this 
work also establishes GDF3 as a secreted extrinsic effector protein acting on myoblasts 
and serving as an exclusively macrophage-derived regeneration factor in tissue repair. 
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INTRODUCTION 
 
Tissues suffer damage during an organism’s lifetime. In order to maintain the body’s 
integrity and homeostasis, it is critically important to achieve complete regeneration. In 
many cases a straightforward paradigm can be applied whereby organ injury induces 
expansion and differentiation of a quiescent population of tissue-specific stem cell-like 
progenitors. Impaired injury-related immune response has been shown to greatly 
influence regeneration in liver, central nervous system or skeletal muscle (Chazaud, 
2014; Duffield et al., 2005; Laflamme and Murry, 2011; Rapalino et al., 1998). Immune 
cells and in particular, macrophages sense the injury, remove damaged tissues, then 
initiate restoration of tissue integrity via promoting repair mechanisms. During this latter 
phase the immune response regulates the reengagement of tissue progenitor cell 
populations to support cell growth and differentiation. Our knowledge is fragmented on 
how macrophages employ sensory and regulatory mechanisms and use effector functions 
to serve their reparatory roles. We sought to identify such integrated regulatory 
mechanisms that equip a macrophage with the capacity to contribute to a timely 
progression of repair.  
We found that the fatty acid regulated transcription factor, Peroxisome Proliferator-
Activated Receptor gamma (PPARγ) (Tontonoz et al., 1998), was required in repair 
macrophages during skeletal muscle regeneration. Mice with a deletion of PPARγ in their 
myeloid lineages showed a pronounced delay in regeneration. PPARγ regulated the 
expression of a secreted factor, GDF3 in repair macrophages. GDF3 deficiency impaired 
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muscle regeneration and recombinant GDF3 enhanced repair in vivo and the fusion of 
primary myogenic precursor cells (MPCs) in in vitro cultures. Our data reveal a PPARγ-
GDF3 pathway with sensory, gene regulatory and effector components in which PPARγ 
in repair macrophages responds to signals and support the timely promotion of tissue 
repair during skeletal muscle regeneration. 
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RESULTS 
 
PPARγ is expressed in macrophages of the cardiotoxin induced skeletal muscle injury 
model 
 
Skeletal muscle possesses robust regenerative capacity, therefore it provides us with an 
excellent model system to study regeneration. The best characterized experimental model 
of skeletal muscle injury is the toxin induced injury and regeneration.  We triggered 
skeletal muscle damage in the tibialis anterior (TA) muscle of mice by intramuscular 
injection of the snake venom, Cardiotoxin (CTX), to induce a homogenous and 
synchronous muscle damage that is repaired with the active contribution of infiltrating 
immune cells. We isolated macrophage populations from injured muscle and interrogated 
their gene expression profiles by microarray analysis. When the expression profiles of 
inflammatory Ly6C+ and repair Ly6C- macrophages derived from injured muscle at day 2 
CTX injury were compared, gene ontology (GO) annotation categories belonging to lipid 
and carbohydrate metabolism dominated the biological processes that were the most 
robustly upregulated in the Ly6C- (repair) macrophages (Fig S1A). When analyzing the 
expression data, we found that a master regulator of metabolism, Pparg, was highly 
expressed in these macrophages. Using publicly available gene expression data within the 
Immunological Genome Project, we compared the expression of Pparg in muscle 
infiltrative macrophages to that of their direct precursors, Ly6C+ monocytes (Varga et al., 
2013), and various other myeloid cells (Fig S1B). We found that Pparg in muscle 
macrophages was highly expressed, and that only two in vivo macrophage subtypes, 
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alveolar macrophages and splenic red pulp macrophages expressed Pparg higher. In 
contrast to Pparg, Ppara was not expressed in muscle infiltrative macrophages, while the 
expression of Ppard showed a declining expression in the course of regeneration (Fig 
S1C). 
Based on these findings, we hypothesized that macrophage PPARγ is a metabolic sensor 
and regulator of skeletal muscle regeneration. To test this hypothesis, we used the 
Ppargfl/fl Lyz2-cre mouse strain, which is deficient in PPARγspecifically in myeloid 
lineages (Clausen et al., 1999). When CD45+ cells, which comprise all infiltrating 
hematopoietic cells, or sorted macrophages, were isolated from injured skeletal muscle, 
the expression of  Pparg was detected in these cells by RT-qPCR (Figs S1D and S1E) in 
wild type (WT) animals. Furthermore, the expression of Pparg was greatly diminished in 
corresponding CD45+ cells and macrophages isolated from Ppargfl/fl Lyz2-cre animals, 
validating the suitability of this genetic model for these experiments.  
 
Macrophage PPARγ regulates skeletal muscle regeneration 
 
Wild Type and Ppargfl/fl Lyz2-cre animals were injected with CTX to induce TA muscle 
injury and then regeneration was analyzed by a combination of morphometric and flow 
cytometry analysis. We found Ppargfl/fl Lyz2-cre animals showed a pronounced delay in 
muscle regeneration (Figs 1A-D and S2A). First, the cross-sectional area (CSA) of the 
regenerating muscle fibers was significantly smaller in the Ppargfl/fl Lyz2-cre than in WT 
mice at day 8 and day 21 following CTX injury (Figs 1C and S2A). Second, there were a 
significantly higher number of phagocytic and/or necrotic fibers present at day 8 post 
 8 
CTX in Ppargfl/fl Lyz2-cre mice (Figs 1A-B), indicating either a delayed clearance of 
dying myofibers or an altered dynamics of muscle fiber death in Ppargfl/fl Lyz2-cre 
animals. Third, increased inflammatory infiltration persisted in small regions in the 
regenerative areas in Ppargfl/fl Lyz2-cre muscles at day 8 (Fig 1A), which were resolved 
by day 21 (Fig S2B). Next, we wanted to ascertain whether PPARγ deficiency in the 
hematopoietic compartment was the major contributor to the observed phenotype. To 
prove this, we used a second genetic model, in which bone marrow from the epiblastic 
conditional ablation of Pparg (Ppargfl/-, Sox2-cre+) (Nadra et al., 2010) or WT animals 
were used to reconstitute the hematopoietic compartment in irradiated WT animals (bone 
marrow transplanted or BMT animals). TA muscles of recipient BMT animals were 
injected with CTX 12 weeks after BMT and histological analysis of muscle regeneration 
was carried out 22 days post injury. When compared with animals that received WT bone 
marrow (WT BMT), mice that received bone marrow deficient in PPARγ (Ppargfl/-, 
Sox2-cre+ BMT) exhibited a profound deficit in regeneration (Figs 1E-F). Further 
underlying the importance of PPARγin muscle regeneration, full body Ppargfl/- Sox2-cre+ 
animals displayed impairment in their skeletal muscle regeneration (Fig S2C).  
 
PPARγdeficiency does not alter macrophage infiltration or differentiation in injured 
muscle 
 
Several possible reasons could explain why macrophage PPARγ deficiency leads to such 
impairment in muscle regeneration. One underlying reason behind our observations could 
be a decreased macrophage infiltration in Ppargfl/fl Lyz2-cre animals. To monitor the 
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cellular dynamics of immune infiltration in CTX injured muscle, we treated WT and 
Ppargfl/fl Lyz2-cre animals with CTX, then isolated and analyzed immune cells from 
injured muscles on days 1, 2 or 4, using CD45+ magnetic bead selection. We found no 
major difference between the numbers and types (Ly6Cmid F4/80- neutrophils, Ly6C+ 
F4/80low and Ly6C- F4/80high macrophages) of infiltrating immune cells in WT vs. 
Ppargfl/fl Lyz2-cre animals (Fig. S3), with the exception of minor alterations in the ratio 
of neutrophils at day 1 and in the total number of CD45+ cells at day 6.  
Next, we wanted to explore which macrophage functions might be relevant to muscle 
regeneration and regulated by PPARγ activity. To test the possible contribution of 
impaired phagocytosis, we used bone marrow derived macrophages (BMDMs) isolated 
from WT, Ppargfl/fl Lyz2-cre or WT BMT and Ppargfl/-, Sox2-cre+ BMT animals (Figs 
S4A-B). We set up a phagocytosis assay, in which fluorescently labeled necrotic C2C12 
myoblasts were co-incubated with BMDMs labeled with a different fluorescent dye. 
Ppargfl/fl Lyz2-cre BMDMs showed no significant increase in the number of phagocyting 
BMDMs or in the amount of phagocytosed substrate as compared with WT BMDMs 
(Fig. S4B). Similar results were obtained using BMDMs derived from WT BMT or 
Ppargfl/-, Sox2-cre+ BMT animals, except that Ppargfl/-, Sox2-cre+ BMT BMDMs were 
able to phagocytose a greater load. Our results indicated that an inadequate phagocytic 
clearance was unlikely to be responsible for the observed delay. 
 
Macrophage PPARγregulates myoblast differentiation in a paracrine manner in vitro 
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These results led us to test if macrophage PPARγ activity confers a yet unidentified 
muscle differentiation-promoting phenotype to macrophages, which could explain the 
observed delayed muscle regeneration in animals deficient in PPARγin macrophages. To 
test this hypothesis, we used in vitro muscle precursor cell proliferation or differentiation 
assays that utilize primary myoblasts isolated from WT mice (Figs 2A-B). In the first 
assay, we cultured primary myoblasts with conditioned medium derived from non-
treated, interferon- (IFN-) or interleukin-4 (IL-4)-treated WT and Ppargfl/fl Lyz2-cre 
BMDMs, in conditions favoring cell proliferation and measured the proliferation index 
by detecting Ki67+ cells by immunofluorescence (IF). As expected, conditioned medium 
derived from IFN--treated WT BMDMs increased myoblast proliferation (Mounier et 
al., 2013).  Conditioned medium from non-treated Ppargfl/fl Lyz2-cre BMDMs 
phenocopied the proliferation enhancing effect of inflammatory WT BMDMs on 
myoblasts (Fig 2A). These results indicate that PPARγin macrophages modulated an 
unknown signaling system that could influence myoblast proliferation in a paracrine 
manner. Next, we tested the effect of BMDM derived conditioned media on the 
differentiation of myoblasts by counting the number of cell nuclei within freshly formed 
desmin positive myotubes cultured in differentiation medium (Fig 2B and Fig S4C). As 
expected, we observed a large increase in differentiation when myoblasts were grown in 
conditioned medium derived from IL-4-treated WT BMDMs. Importantly, this increased 
differentiation was abrogated when conditioned medium from IL-4-treated Ppargfl/fl 
Lyz2-cre BMDMs was added to differentiating myoblasts. This effect was seen in 
several, independently isolated primary myoblast cell lines that were used for the 
experiments (Fig S4C). BMDM supernatant derived from IFN--treated cells, on the 
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other hand, did not alter myoblast differentiation (Fig S4D). Our results raised the 
possibility that similar PPARγdependent paracrine signaling events took place in situ 
during regeneration, where muscle infiltrative macrophages and MPCs might interact to 
achieve a synchronized and timely regeneration. 
 
PPARγ regulates cell type specific genes in muscle infiltrating macrophages 
 
Next, we set out to identify PPARγdependent regulatory circuits that connect 
macrophages to myotube differentiation in a paracrine manner. As PPARγis a 
transcription factor, we presumed that a relevant change in the gene expression in muscle 
macrophages must shed light on the regulatory circuit that is abrogated in Ppargfl/fl Lyz2-
cre macrophages. We isolated populations of macrophages from regenerating muscle 
from WT and Ppargfl/fl Lyz2-cre animals and analyzed their gene expression profiles by 
microarrays (Figs 2C-E and S4E-F). We selected inflammatory Ly6C+ macrophages at 
day 1 and 2, and repair Ly6C- macrophages at day 2 and 4 post CTX injury and compared 
their gene expression by 2 way ANOVA tests (Table S1). We created heat maps for all 4 
examined macrophage subsets (Fig 2C). These heatmaps show all genes that were 
differentially expressed in one relevant subset and also show the expression pattern of 
these genes in all the other macrophage subsets. The top 5 genes that were most 
differentially regulated in WT vs. Ppargfl/fl Lyz2-cre cells are shown in Fig. 2D. The 
number of genes that were concordantly regulated in a PPARγmediated manner in more 
than one macrophage subtypes is shown in Fig. 2E. We hypothesized those genes could 
be under regulation by PPARγ that were expressed differently in more than one subtype 
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of muscle macrophages. Accordingly, we combined the lists of upregulated genes 
reported by the ANOVA analysis of WT vs. Ppargfl/fl Lyz2-cre comparisons. Although 
many genes were differentially regulated in a single type of muscle macrophages, only 5 
genes (Saa3, Hebp1, Plxnd1, Apold1, Tsg101) were upregulated in all 4 investigated 
subtypes of PPARγdeficient muscle macrophages (Fig 2E and table S1). Next, we 
analyzed the gene sets that were downregulated in Ppargfl/fl Lyz2-cre macrophages. There 
was only 1 gene, namely Growth differentiation factor 3 (Gdf3), that was consistently 
downregulated in all 4 investigated macrophage populations (Figs 2D-E). Thus, we 
identified several putative PPARγtarget genes that showed consistent PPARγ 
dependency in more than one muscle macrophage subsets. To ascertain the 
PPARγdependent regulation of some representative genes, we measured the mRNA 
expression of Gdf3, Apold1, Hebp1 and Plxnd1 by RT-qPCR in macrophage subsets 
sorted from injured muscle (Fig S5A). This analysis confirmed the results derived from 
the microarray experiments. The expression pattern of a short panel of previously 
described PPARγ-dependent (M2) alternative genes (Odegaard et al., 2007) indicated that 
the repair macrophages in CTX injured muscles were not canonical M2 macrophages, 
and that PPARγ exerted little, if any, influence on their expression (Fig S5B). Along the 
same line, while a total body deficiency in STAT6, the master regulator of IL4 signaling, 
caused increased presence of phagocytic and/or necrotic fibers at day 8 (Fig S5C), it did 
not affect the CSA of new myofibers (Fig S5D).  
The genes we identified as PPARγ-dependent in muscle macrophages did not belong to 
the group of canonical PPARγregulated genes described in various myeloid cells in 
earlier studies (such as Plin2, Cd36, Angptl4 or Fabp4) (Szanto et al., 2010; Welch et al., 
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2003). One possible reason for this discrepancy could be that most in vitro studies apply 
synthetic or natural ligands of PPARγto study the transcriptional activity of the receptor 
upon ligand activation. Therefore, we wanted to see if synthetic PPARγligand activation 
of infiltrating macrophages gave rise to transcriptional changes that are more reminiscent 
of the list of previously identified PPARγtarget genes. For this reason we treated WT 
animals with rosiglitazone (RSG) via gavage and analyzed the ligand dependent gene 
expression changes in macrophages (Figs S4F and S5E, and Table S1). We found that 
many more genes were regulated by RSG treatment in Ly6C+ than in Ly6C- cells. Again, 
the genes that showed differential expression upon RSG treatment in Ly6C+ cells did not 
contain established PPARγregulated genes, nor the 6 differently regulated genes that 
appeared to be under PPARγregulation in all macrophage subsets. Although RSG 
treatment caused the differential regulation of fewer genes in Ly6C- cells, the most 
robustly upregulated gene was Angptl4, one of the best-characterized PPARγtarget 
genes. This suggests that not only Ly6C- macrophages at day 2 expressed PPARγ, but 
that the receptor was also sensitive to the activating effect of an exogenous ligand in 
Ly6C- cells. It is important to note that Gdf3, the gene that was found to be consistently 
downregulated in Ppargfl/fl Lyz2-cre macrophage subsets, was also regulated by RSG 
treatment (only) in Ly6C- macrophages. Next, we took the list of 43 genes that showed 
ligand dependent upregulation in Ly6C- macrophages upon RSG treatment and created a 
heat map representation to see how these genes were regulated in the absence of RSG 
treatment (Fig S5E). Even without RSG treatment, most of the otherwise RSG dependent 
genes showed a characteristic induction as Ly6C+ macrophages differentiated into Ly6C- 
cells and an even further induction by day 4. This observation raised the intriguing 
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possibility that the underlying reason behind the limited number of PPARγligand 
regulated genes in Ly6C- macrophages was that most of these genes were already 
induced during muscle regeneration, even in the absence of exogenous synthetic ligand 
treatment. Related to this hypothesis, we detected a dynamic in situ regulation of 
eicosanoid synthesis during regeneration. While inflammatory eicosanoids (e.g. PGE2 
and PGF2α) were detectable in the early inflammatory stages of injury, they were later 
replaced by lipid mediators produced by murine 12/15-lipoxygenase (Alox15) that have 
been implicated in ligand activation of PPARγ such as 12-HETE and 15-HETE (Fig. 
S5F) (Huang et al., 1999). 
 
GDF3 is a macrophage-derived PPARγdependent member of the TGF-ß family 
 
To focus on putative PPARγregulated genes whose activity could promote muscle 
regeneration, we interrogated the list of differently expressed genes for genes that (1) 
were PPARγdependent in more than one macrophage subset, (2) coded a secreted factor 
and (3) whose activity might be linked to muscle differentiation. Of note, one gene, Gdf3 
(Levine and Brivanlou, 2006; Levine et al., 2009; Shen et al., 2009), fit all these criteria. 
Gdf3 was statistically significantly downregulated in Ppargfl/fl Lyz2-cre cells in all four 
investigated macrophage subsets (Figs 2 D-E, Table S1). GDF3 belongs to the TGF- 
family, whose members are secreted factors acting in a paracrine manner. Finally, several 
members of the TGF- family are known regulators of muscle regeneration, including 
GDF8 (also known as Myostatin) (McPherron et al., 1997). Therefore, we selected Gdf3 
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as the most likely PPARγdependent gene that contributes to muscle regeneration for 
further analysis. 
 
PPARγoccupies a complex set of active enhancers around the Gdf3 locus 
 
Next, we wanted to characterize the genomic events that are responsible for the 
regulation of Gdf3 by PPARγ. We elected to use BMDMs, a readily available in vitro 
model system that allowed us to employ high-throughput genomic and epigenomic 
methods to interrogate the regulatory mechanism exerted by PPARγon the Gdf3 locus. 
We established that WT and Ppargfl/flLyz2-cre BMDMs provided a platform with good 
correlation to study the PPARγdependent regulation of Gdf3, as PPARγdeficiency in 
BMDMs abrogated the expression of both the canonical PPARγtarget gene Angptl4 and 
that of Gdf3 (Fig 3A). Then, we compiled epigenomic and genomic data to identify the 
relevant enhancers that were active and possibly under PPARγregulation in BMDMs 
(Fig 3B). We included CTCF as a binding factor of insulator regions and RAD21, as a 
component of the cohesin complex to determine the boundaries of potential chromatin 
loops or topological domains, PU.1 as a key lineage determining factor in macrophages, 
RXR (the obligate heterodimeric partner of PPARγ), and PPARγChIP-seq data derived 
from thioglycolate elicited peritoneal macrophages and adipocytes. We combined these 
data with active epigenetic marks from H3K4me3 ChIP-seq experiments and GRO-seq 
data from BMDMs. Based on the common CTCF and RAD21 binding sites (Daniel et al., 
2014; Merkenschlager and Odom, 2013), the transcription unit of Gdf3 appeared to be 
approximately between approximately -50 kb to +50 kb. Our definition of putative, active 
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enhancers included: (1) binding of PU.1, (2) presence of detectable enhancer transcript 
(GRO-seq signal) (3) RXR or PPARγbinding. This approach was validated by applying 
the same criteria to the Angptl4 locus, in which we readily identified its 
PPARγdependent enhancer (Fig S6A). Based on these criteria we nominated 14 putative 
active enhancers at a distance from +38 Kb to -47 Kb relative to the transcription start 
site of Gdf3 (Figs 3B and S6B). As we show in Fig 3C, binding of PPARγand RXR 
could be readily detected on 5 of these selected enhancers (at +7.3 kb, -21kb, -25kb, -
44kb and -47kb) if we compared WT to Ppargfl/fl Lyz2-cre BMDMs. These data strongly 
suggested that Gdf3 was regulated by one or several of these PPARγ:RXR binding sites.  
 
GDF3 is a regulator of myoblast proliferation, differentiation and muscle regeneration 
 
Next, we analyzed the GDF3 protein expression in whole muscle lysates of CTX injured 
WT mice, which provided a snapshot of GDF3 protein level during regeneration. The 
protein expression followed the induction seen at the mRNA level in macrophages and 
showed a pronounced induction, which peaked at day 4 (Fig 4A), at the time when 
inflammation subsides and regenerative processes start to dominate within the injured 
muscle. Importantly, the induction of GDF3 expression was detectable in the CD45+ 
(hematopoietic) compartment and was diminished at both mRNA and protein amount in 
Ppargfl/fl Lyz2-cre animals (Figs 4B-D). Next, we further investigated GDF3 expression 
in alternative models of muscle injuries. We found that, similarly to CTX injury, GDF3 
protein expression was induced during glycerol mediated injury and regeneration in WT 
but diminished in PPARγmacrophage deficient animals (Fig 4E). Furthermore, not only 
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the mRNA expression of Gdf3, but the entire panel of genes that showed strong 
PPARγdependency in the CTX model, was regulated concordantly in the two models of 
injury (Fig 4F). GDF3 protein expression was also induced in muscle samples exposed to 
exposed to crush- and freeze-injuries, which a toxin-free methods (Fig 4G). Due to recent 
publications that reported a high tendency for false positive detection of GDF proteins in 
protein detection applications (Egerman et al., 2015), it is important to note that the 
GDF3 protein induction during CTX injury was undetectable in muscle samples from 
Gdf3-/- animals (Fig 4H). o summarize, GDF3 is a macrophage-derived protein whose 
expression is induced in various models of muscle regeneration in a PPARγdependent 
manner.  
According to our model, the regeneration delay in macrophage PPARγ deficient animals 
was, at least partly, attributable to a diminished macrophage derived GDF3 secretion 
within regenerating muscles. This model posits that GDF3 deficiency in macrophages 
should yield impairment in regeneration comparable to what was observed in Ppargfl/fl 
Lyz2-cre animals. Indeed, muscle regeneration after CTX injury was altered in full body 
Gdf3-/- animals at day 8 (Figs 5A-B). It has been reported that the full body deletion of 
Gdf3 shows incomplete penetrance (Shen et al., 2009), which suggests possible 
compensatory mechanisms. To limit their involvement and ascertain the hematopoietic 
source of GDF3 during muscle regeneration, we generated BMT animals reconstituted 
with Gfd3-/- BM. When the GDF3 chimeric animals were challenged with CTX induced 
muscle injury, they exhibited impairment in regeneration at day 16 and 20 (Figs 5C-D). 
When compared with WT BMT animals, Gdf3-/-  chimeras contained more regenerating 
myofibers with smaller CSA and the regenerating muscle was replete with lipid 
 18 
accumulations, which are hallmarks of defective muscle regeneration (Figs 5C-D). Other 
cell types, such as fibro-adipogenic progenitors (FAPs) are involved in muscle 
regeneration (Heredia et al., 2013; Lemos et al., 2015). In line with our results from the 
Gdf3-/- BMT experiment (Figs 5C-D) and with the mRNA and protein expression data 
showing GDF3 expression in the CD45+ compartment (Fig 4), Pdgfra expressing FAP 
cells isolated from D2 regenerating muscle barely expressed Gdf3 and Lyz2 mRNA (Fig. 
5E), rendering the involvement of FAPs unlikely in the macrophage derived GDF3-
driven effects on muscle regeneration.  
To further prove the requirement for GDF3 in muscle regeneration, we injected 
recombinant GDF3 into CTX injured muscles of Ppargfl/fl Lyz2-cre mice. We found that 
the exogenously added GDF3 rescued the regeneration deficit seen in these animals (Fig 
6A-B). To characterize the function of GDF3 in detail, we cultured primary myoblasts 
with or without recombinant GDF3. We found GDF3 slightly decreased myoblast 
proliferation (Fig 6C, left panel). We detected an even more robust effect of GDF3 on 
myotube formation, as myoblast cultures showed a pronounced increase in their fusion 
index in the presence of GDF3 (Figs 6C, right panel, and 6D). Myotube formation 
depends on cell motility, terminal differentiation and cell fusion. In a specific fusion 
assay, we showed that GDF3 was a potent inducer of myotube formation (Fig S7A), 
while a differentiation assay indicated that GDF3 did not affect the terminal 
differentiation of myoblasts into myocytes (Fig S7B).  
Next, we investigated if the SMAD2 phosphorylation pathway, which is involved in the 
signal transduction of several TGF-β superfamily members, is engaged during muscle 
regeneration. We found a detectable induction of in situ pSMAD2 signals in muscles at 
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day 4 of regeneration (Fig 7A), at the time when GDF3 expression peaked in the injured 
muscle. Furthermore, SMAD2 phosphorylation was significantly increased during in 
vitro treatment of primary myoblasts with GDF3 (Figs 7B-C). 
In search for the molecular changes triggered in muscle progenitors in the presence of 
GDF3, we differentiated in vitro primary myoblasts with or without GDF3 and 
interrogated the gene expression changes by RNA-Seq. First, we compared the profile of 
primary myoblasts and myoblast-derived myotubes that were cultured in the presence or 
absence of GDF3. The expression pattern of a preselected list of genes relevant to muscle 
differentiation (Fig 7D) validated our experimental system. Next, we compared the 
expression profile of differentiating myotubes cultured with or without GDF3. The list of 
the differentially regulated genes (Fig 7E and Table S2) showed that a limited set of 
transcripts were either induced or repressed in the presence of GDF3. Several of the 
differentially regulated genes, including Bex1, (Jiang et al., 2016; Koo et al., 2007), Sgca 
(Matsumura et al., 1992) and Camk1g, have been implicated in muscle regeneration, 
muscle structure and/or Ca2+ homeostasis, showing that macrophage derived GDF3 could 
elicit biologically relevant changes during muscle regeneration.  
If GDF3, a macrophage derived secreted factor can regulate in vitro and in situ muscle 
differentiation and regeneration, then we wanted to ask if GDF3 is the only macrophage-
derived TGF- family member that is relevant in the context of CTX induced muscle 
injury. Therefore, we reanalyzed the transcriptomic features of muscle infiltrative 
macrophages to chart the expression and dynamics of the TGF- family signaling system 
(Fig 7F and Fig S7C). Three ligands (Gdf3, Gdf15 and Inhba) showed notable gene 
expression dynamics in muscle infiltrative macrophages. GDF3 expression peaked in 
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repair macrophages and showed definitive, consistent regulation by PPARγ. The two 
other family members (FigS7C), Gdf15 and Inhba, were also regulated during muscle 
regeneration, and both genes exhibited partial PPARγdependency. The PPARγ-GDF3 
regulatory axis described in this study therefore identifies a sensory-regulatory-effector 
mechanism, by which macrophages are regulators of the tissue progenitor compartment, 
namely MPCs. This axis orchestrates tissue regeneration, possibly in unison with other 
members of the TGF- family, leading to synchronous regeneration. 
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DISCUSSION 
 
Skeletal muscle possesses excellent regenerative capacity, therefore it was striking to see 
that after CTX injury full body Ppargfl/- Sox2-cre animals showed signs of residual 
inflammation and impaired regeneration. The true extent of the involvement of 
macrophage PPARγ in the regeneration failure in these animals is unclear for several 
reasons, including the uncharacterized, but presumably inflammatory state of these 
animals and the potential involvement of non-macrophage (e.g. muscle) PPAR in 
regeneration. Therefore we used two distinct genetic models (BMT and conditional 
PPARγ deficiency, Ppargfl/fl Lyz2-cre), which allowed us to focus on the role of 
PPARγin macrophages. The delay in regeneration in macrophage PPARγdeficient 
animals was less profound than in the epiblastic Pparg-/- mice, yet it was detectable as 
long as three weeks after the initial injury, thus appearing to be among the most dramatic 
reported deficiencies in regeneration caused by impairments in macrophage functions 
(Mounier et al., 2013).  
Our analysis did not reveal a gross difference in macrophage number or differentiation in 
Ppargfl/fl Lyz2-cre animals, unlike two other reported experimental systems where AMPK 
or IGF1 deficiency in muscle infiltrative macrophages led to altered macrophage 
differentiation (Mounier et al., 2013; Tonkin et al., 2015). Although alternatively 
activated macrophages have been implicated in tissue repair and PPARγ has been 
reported to be a regulator of alternative macrophage polarization (Odegaard et al., 2007), 
we have previously reported that muscle Ly6C+ and Ly6C- macrophages do not 
correspond to canonical alternatively polarized macrophage populations (Varga et al., 
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2016) in the CTX model. Therefore it is not surprising that, in this model PPAR is 
controlling  genes other than alternative macrophage related ones, reported to be 
PPARγdependent in other tissue compartments and contexts (Odegaard et al., 2007). 
The fact that the regeneration impairment in Stat6-/- animals did not manifest in a 
decrease in CSA, also suggest that PPARγin this experimental context, acts through 
mechanisms other than modulating alternative macrophage activation. Systematic 
transcriptomic analyses, however, provided clues about both the sensory and the 
regulatory roles of PPARγin muscle infiltrating macrophages. It is important to stress 
that earlier descriptions of direct PPARγ transcriptional target genes often reported lipid 
metabolic genes as the main targets PPARγof in macrophages, which could poorly 
explain the anti-inflammatory role of the receptor (Szanto et al., 2010; Welch et al., 
2003). We report here that the transcriptional activity of PPARγ is unique in muscle 
macrophages, because the most robustly changing genes (such as Saa3, Hebp1) were 
linked to inflammation, rather than to lipid metabolism. Second, in vivo treatment with 
RSG identified the Ly6C- repair macrophages as an in situ macrophage subtype that 
could be activated by a synthetic ligand for PPARγ. The surprising fact that RSG 
treatment elicited characteristically different gene expression changes in Ly6C+ and 
Ly6C- macrophages isolated from the same tissue and timepoint underscores the notion 
that distinct macrophage subsets have differential responses to environmental cues.  A 
possible interpretation of the available data would be the involvement of a yet 
unidentified endogenous ligand for PPARγwhose activity is restricted to the Ly6C- 
compartment, which could explain the tendency of otherwise RSG inducible genes to be 
upregulated in the Ly6C- macrophages even in the absence of the synthetic ligand. 
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Whether the dynamic regulation of in situ eicosanoid synthesis we detected during 
regeneration could be behind the apparent ligand activation of the receptor, requires 
further investigation.  
From the perspective of muscle regeneration, the most notable finding was the 
identification of GDF3, a TGF- family member, which showed consistent regulation by 
PPARγin all relevant macrophage subtypes. To ascertain that GDF3 was not only a 
PPARγ dependent factor, but also a direct PPARγtarget, we analyzed an extensive range 
of genomic and epigenomic data. Although it is clear that GDF3 is expressed in a 
PPARγ-dependent fashion and can be induced by ligand in muscle derived Ly6C- 
macrophages, direct regulation by PPARγis challenging to prove, because ligand 
dependent regulation appears to be macrophage subtype specific and not detectable in 
BMDMs. However, we have provided data that are consistent with direct regulation, even 
in BMDMs.  
It is noteworthy, that both GDF3 gene and protein expressions were much lower in the 
CD45- fraction isolated from injured muscle than in the hematopoietic compartment. 
Considering that the separation of CD45+ cells is inherently incomplete, our results 
indicate that macrophages are the predominant, if not the only source of GDF3 within the 
injured tissue. This exclusivity sets GDF3 apart from other macrophage derived 
regenerative factors, such as IGF1 (Tonkin et al., 2015), which is also produced by 
muscle and in the liver upon injury. The timing and localization of GDF3 protein in the 
CTX and other, unrelated injury models firmly suggested that GDF3 is a general, 
macrophage specific regulator of muscle regeneration.  
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To link macrophage biology to tissue regeneration, we analyzed the role of macrophage 
derived GDF3 in muscle regeneration in a combination of in vivo and in vitro approaches. 
Foremost, two genetic models of GDF3 deficiency reported a delay in regeneration. 
While the decrease in average CSA in Gdf3-/- animals was comparable to that seen in 
Ppargfl/fl Lyz2-cre animals, Gdf3-/- animals did not display persistent inflammation and 
delayed resolution of necrotic and/or phagocytic fibers. This suggested that PPARγ 
regulated several relevant pathways during regeneration. Notably, a gain of function 
experiment revealed that exogenous GDF3 could counteract the deleterious effect PPARγ 
deficiency in macrophages. Our in vitro results with BMDM supernatants and myoblasts 
indicated the presence of a regulatory circuit between macrophages and muscle cells and 
showed that GDF3 appeared to be an especially robust enhancer of myoblast fusion.  
As other cell types are also involved in the regeneration process (Heredia et al., 2013; Joe 
et al., 2010; Uezumi et al., 2010), it cannot be excluded that GDF3 is only one of the 
TGF-β family members that are active during regeneration and that it has effects on other 
cell types such as FAPs as well. It is remarkable, though, that the key elements of the 
myogenic cross talk between cell types can be modeled in vitro using macrophages and 
myoblasts only, arguing that these two cell types and their interactions are critical to 
support regeneration.  
Our findings also carry potential implications for pathological circumstances in which 
recurrent muscle damage and asynchrony in repair due to genetic conditions leads to 
debilitating degenerative muscle diseases, such as Duchenne Muscular Dystrophy 
(DMD). It is of great importance to determine if GDF3 is also a regulator of muscle 
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regeneration in DMD or other types of myopathies, which are most of the time associated 
with the permanent presence of inflammatory cells, especially macrophages.  
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MATERIALS AND METHODS 
 
For more detailed descriptions of experimental procedures, please see supplemental 
materials and methods.  
Mice.  
Ppargfl/flLyz2-cre+ and wild type C57BL/6J controls, Ppargfl/-Sox2-cre+ and 
littermate control Ppargfl/+Lyz2-cre- animals, and Gdf3-/- and littermate C57BL/6 albino 
controls were used in the experiments. All experimental procedure conducted on animals 
were carried out in accordance with institutional regulations. 
Muscle injury. Mice were anaesthetized with isoflurane and 50 µl of cardiotoxin 
(12X10-6 mol/l in PBS) was injected in the tibialis anterior (TA) muscle. Muscles were 
recovered for flow cytometry analysis at day 1, 2 or 4 post-injury or for muscle histology 
at day 8 post-injury.  
Histological analysis of muscle regeneration. Muscles were removed and snap 
frozen in nitrogen-chilled isopentane (–160°C). 8 µm thick cryosections were cut and 
stained with hematoxylin-eosin (HE). HE stained sections were analyzed for cross 
sectional area (CSA) or for the presence of phagocytic fibers. Day 8 post CTX slides 
were also IF stained for Desmin / F4/80 / DAPI.    
 Macrophage cell culture for conditioned medium generation. Macrophages 
were obtained from bone marrow (BM) precursor cells that were were cultured in 
DMEM medium containing 20% FBS and 30% conditioned medium of L929 cell line 
(enriched in CSF-1) for 7 days. Macrophages were activated with IFN- (50 ng/ml) or IL-
4 (10 ng/ml) to obtain macrophage-conditioned medium.  
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 Myogenic precursor cell (MPC) culture. Murine MPCs were obtained from TA 
muscle and cultured using standard conditions in DMEM/ F12 (Gibco Life Technologies) 
containing 20% FBS and 2% Ultroser G (Pall Inc). For proliferation studies, MPCs were 
incubated for 1 day with conditioned medium + 2.5% FBS or with 2.5% FBS medium 
containing GDF3 mouse recombinant protein. Cells were then incubated with anti-ki67 
antibodies (15580 Abcam), which were subsequently visualized using cy3-conjugated 
secondary antibodies (Jackson Immunoresearch Inc). For differentiation studies, MPCs 
were incubated for 3 days with conditioned medium containing 2% horse serum or with 
2% horse serum medium containing GDF3. Cells were then incubated with anti-desmin 
antibodies (32362 Abcam), in combination with a cy3-conjugated secondary antibody 
(Jackson Immunoresearch Inc). 
 Phagocytosis assay: BMDM cells and C2C12 cells were stained with CellVue or 
PKH67 (Sigma), respectively. Heat killed stained C2C12 were used as phagocytic 
substrates for stained BMDMs and fluorescent intensity was measured with a 
FACScalibur instrument. 
  Image capture and analysis for myoblast cultures. Fusion index (for myogenic 
cells) was calculated as the number of nuclei within myotubes divided by the total 
number of nuclei, nuclei number being estimated using the Image J software. 
Isolation of macrophages from muscle. CD45+ cells were isolated from CTX 
injected muscles using magnetic sorting (Miltenyi Biotec). CD45+ cells then were labeled 
with fluorescently labeled antibodies and Ly6C+ F4/80low macrophages, Ly6C- F4/80+ 
macrophages and Ly6Cmid F4/80- neutrophils were analyzed and sorted with a BD 
FACSAria III sorter.  
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RNA isolation from sorted MFs. Macrophage subsets were sorted from day 1, 2 
and 4 post-injury muscles with a FACSAria III sorter and total RNA was isolated with 
TRIZOL reagent according to the manufacturer’s recommendation.  
 Microarray analysis of muscle macrophages: Global expression pattern was 
analyzed on Affymetrix GeneChip Mouse Gene 1.0 ST arrays. The microarray data are 
publicly available (Data access: GSE71155). 
 ChIP (Chromatin immunoprecipitation): ChIP was carried out in BMDMs 
using antibodies against pre-immune IgG (Millipore, 12-370), (pan) RXR (sc-774 Santa 
Cruz Biotechnology) and PPARγ (Perseus #PP-A3409A). 
Bioinformatic analysis of the active enhancers around the Gdf3 and Angptl4 
locus: The list of published and/or publicly available datasets used for visualization in 
IGV2 to identify active enhancers can be found in the supplemental method section.  
 Western Blotting: GDF3 protein expression was measured using Western Blot 
analysis. Samples from CTX injected TA muscles or CD45+ cells were lysed in RIPA 
buffer. GDF3 was targeted using rabbit monoclonal Anti-GDF3 primary antibody 
(ab109617, Abcam, Cambridge, MA) at 1:1,000 dilution in TBS-T supplemented with 
5% BSA overnight at 4°C. Anti-GAPDH mouse monoclonal primary antibody (AM4300, 
Ambion, Carlsbad, CA) was used as a protein loading control at 1:10,000 – 1:20,000 
dilution in TBS-T supplemented with 5% BSA overnight at 4°C.  
 RNA sequencing (RNA-Seq) library preparation for myoblast gene 
expression analysis: cDNA library for RNA-Seq was generated from 1g total RNA 
using TruSeq RNA Sample Preparation Kit (Illumina, San Diego, CA, USA) according to 
the manufacturer’s protocol.  
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The RNA-Seq data are publicly accessible (data access: 
PRJNA290560/SRR2136645). 
General statistical analyses. All experiments were performed using at least three 
different samples. Student’s t-tests and 2 way ANOVA analyses were performed and 
P<0.05 was considered significant (P≤0.05=*, P≤0.01=**, P≤0.0001=***, 
P≤0.001=****). Mean and SD values, or mean and SEM values are shown in graphs. 
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FIGURE LEGENDS 
 
Fig 1. Impaired regeneration of skeletal muscle in PPARγ deficient animals. (A) 
Representative images of HE stained skeletal muscle from WT and Ppargfl/fl Lyz2-cre 
animals prior (day 0) or post CTX induced injury (day 8) are shown. Asterisk labels 
phagocytic and/or necrotic fibers and arrow points to foci of inflammatory infiltrations. 
IHC detection of desmin (red), F4/80 (green) and nuclei (blue) at day 8 post CTX injury 
is also shown. Scale bars in the upper left represent 50 μm. (B) The ratio of phagocytic 
and/or necrotic fibers relative to all regenerative fibers at day 8 of regeneration in WT 
and Ppargfl/fl Lyz2-cre muscle sections is shown. (C) Fiber size repartition of regenerating 
muscle in WT or Ppargfl/fl Lyz2-cre animals at day 8 and day 21 post CTX injury. (D) 
Average fiber cross section area (CSA) of regenerating muscle at indicated timepoints 
post CTX injury in WT and Ppargfl/fl Lyz2-cre animals. (E) Representative images of HE 
stained skeletal muscle 22 days after CTX injury from bone marrow transplanted (BMT) 
animals that received either WT or Ppargfl/- Sox2-cre bone marrow. n=4 or 4, 5 or 6, 5 or 
5 and 5 or 5 muscles for WT or Ppargfl/fl Lyz2-cre mice, respectively, at day 0, 8, 21 and 
63.  (F) Muscle fiber CSA of BMT animals 22 days post CTX injury. n= 8 muscles for 
both genotypes. In all bar graphs, mean values +/- SEM are shown. For Pparg expression 
in macrophages and CD45+ cells and for additional histological analysis, see Fig S1 and 
S2. For the FACS analyses of infiltrating cells see Fig S3. 
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Fig 2. PPARγ regulated macrophage functions and genes. (A) Effect of BMDM 
derived conditioned media on the proliferation of primary myoblasts (+/- SEM). n= 4 or 3 
for WT or Ppargfl/fl Lyz2-cre BMDM supernatant. (B) Effect of BMDM derived 
conditioned media on the differentiation of primary myotubes (+/- SEM). For the 
complete analysis, see Figs S4C-D. n=6 for both genotypes. (C-E) Transcriptional 
analysis of the Ly6C+ and Ly6C- macrophage populations derived from WT and Ppargfl/fl 
Lyz2-cre animals. For schematics of comparisons, see Fig S4F. (C) Heatmap 
representation of genes that show differential (p=0.05, min. 1.5X FC) expression in the 
four sorted WT vs. Ppargfl/fl Lyz2-cre macrophages in day 1 Ly6C+, D2 Ly6C+ and D2 
Ly6C-, and D4 Ly6C- cells (labeled as D1 Ly6C+ etc.). In each heatmap, the differentially 
expressed genes are highlighted within a red square and the expression pattern of these 
genes in the other macrophage subtypes is also shown for reference. Blue and red arrows 
label genes that are downregulated or upregulated in WT vs. Ppargfl/fl Lyz2-cre cells, 
respectively. The blue and red arrows point to the direction of increasing fold change 
difference. For RT-qPCR validation of mRNA expression, see Fig S5. (D) Top 5 up and 
downregulated genes in the four sorted macrophage populations in Ppargfl/fl Lyz2-cre 
macrophages. Table lists gene symbols and fold change differences (FC). Gdf3 and 
Apold1, the genes that are down-, or upregulated in Ppargfl/fl Lyz2-cre in all four 
subtypes, are highlighted in color. (E) Venn-diagrams show the overlap of the number of 
genes that are down-, or upregulated in Ppargfl/fl Lyz2-cre macrophages in the four 
analyzed populations. 
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Fig 3. Gdf3 is a PPARγ target gene in BMDMs. (A) mRNA expression of Angptl4, a 
canonical PPARγ target gene, Pparg, Gdf3 and Apobec1, a nearby, not regulated gene, 
are shown in BMDMs (n=4 for WT and n=5 for Ppargfl/fl Lyz2-cre). (B) Identification of 
possible enhancers around the Gdf3 locus. The selection criteria for enhancers possibly 
involved in Gdf3 regulation are described in the text and in Figs S6A-B. Putative 
enhancers are labeled by vertical lines. Blue verticals highlight enhancers without PPARγ 
ChIP enrichment, red verticals label enhancers where enrichment in PPARγ binding in 
WT BMDMs was detected by PPARγ ChIP. (C) ChIP on the putative enhancer regions 
reveal PPARγ binding at +7.3 Kb, -21 Kb, -25 Kb, -44 Kb and -47 Kb enhancers around 
the Gdf3 locus. Representative graphs showing PPARγ, RXR or IgG ChIPs carried out on 
2 samples are shown. Angptl4 enhancer and Gdf3 +16 kB enhancer are shown as positive 
and negative controls, respectively. 
 
Fig. 4. GDF3 mRNA and protein expression in regenerating muscles. ES and B stand 
for embryonic stem cells and blank, respectively. (A) GDF3 protein expression in whole 
muscle lysates of regenerating muscles from WT mice at different timepoints (D=day). 
(B) GDF3 mRNA expression in CD45+ and CD45- cells isolated at day 4 post CTX injury 
from WT and Ppargfl/fl Lyz2-cre mice (M=mouse). (C) Decreased protein expression of 
GDF3 in CD45+ cells isolated from Ppargfl/fl Lyz2-cre animals. (D) mRNA expression of 
Gdf3 in CD45+ and CD45- cells isolated from injured muscles at days 1, 2 and 4 post 
CTX in WT and Ppargfl/fl Lyz2-cre animals. n=4 for each day, cell type and genotype. (E) 
GDF3 protein expression detected in muscles lysates generated from glycerol mediated 
injuries (M=mouse). (F) Concordant mRNA expression pattern of PPARγ-dependent 
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genes in CTX and Glycerol mediated injuries. n=3 for both treatments. (G) GDF3 protein 
expression detected in muscle lysates generated from crush or freeze injuries (R and L 
stand for right and left leg, respectively). (H) Specificity of the anti-GDF3 antibody is 
demonstrated in day 4 CTX injured WT and Gdf3-/- muscle samples. 
 
Fig 5. GDF3 deficiency impairs muscle regeneration. (A, B) Myofiber CSA repartition 
(A) and mean CSA (B) in CTX injured WT or Gdf3-/- muscles at day 8. N=7 or 7 muscles 
for WT or Gdf3-/- mice. (C) Representative HE stained muscle sections of WT BMT and 
Gdf3-/- BMT animals, 16 days post CTX injury. Scale bars represent 50 μm. n= 4 muscles 
for both timepoints and genotypes. (D) Myofiber CSA measurement in WT BMT and 
Gdf3-/- KO BMT animals, 16 and 20 days post CTX injury. (E) Lack of Gdf3 and Lyz2 
mRNA expression in PDGFRA+ FAPs isolated from regenerating muscle at day 2 post-
injury n=3. 
 
Fig 6. Effects of recombinant GDF3 on muscle differentiation. (A, B) Improvement in 
regeneration by administration of recombinant GDF3 in Ppargfl/fl Lyz2-cre animals. (A) 
HE stained images and (B) CSA measurements are shown. (C) In vitro proliferation and 
differentiation assays on primary myoblasts in the presence of recombinant GDF3. n=4. 
(D) IF against Desmin (red) and DAPI (blue) shows a drastic enhancement of myotube 
formation in the presence of recombinant (r) GDF3 in the in vitro primary myoblast 
myogenesis assay n=3. In all bar graphs, bars represent mean +/- SEM. For the effect of 
rGDF3 on myogenic differentiation and fusion, see Fig S7. Scale bars represent 50 μm in 
each image in Fig. 6A and D. 
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Fig 7. Effects of GDF3 on myogenesis. (A) Increased pSmad2 phosphorylation in 
regenerating muscles peaking at day 4 post CTX injury. (B-C) Increased Smad2 
phosphorylation in primary myoblasts treated with rGDF3. IF images and % of pSMAD2 
positive cells are shown. n=3. (D) Heatmap representation of the expression changes of 
myogenic genes validating the utilized in vitro primary myoblast assay. (E) Heatmap 
representation of genes that are differentially expressed (min. fold change difference of 
1.2X between differentiated myoblasts +/- rGDF3) in the presence of recombinant GDF3 
during myoblast differentiation. (F) Heatmap representation of members of the TGF-β 
superfamily signaling system that are expressed and regulated, or expressed but not 
regulated in muscle derived macrophages. For non-expressed members, see Fig S7C. 
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Fig S1. related to Figures 1 and 2. PPARG in muscle infiltrative macrophages 
during skeletal muscle regeneration (A) GO analysis of the genes that are upregulated 
as inflammatory Ly6c+ macrophages differentiate into regenerative Ly6c- macrophages 
during muscle regeneration at day 2 past CTX injury. (B) Expression of Pparg in various 
macrophages and dendritic cells. Microarray data derived from muscle derived 
macrophages isolated for this study and various myeloid cell populations isolated within 
the Immunological Genome Project were pooled and normalized together (per gene 
normalization to the median expression level of Pparg). A selected set of samples and 
their normalized expression value are shown. The commonly used macrophage model, 
bone marrow derived macrophages, are highlighted in light blue, while the high Pparg 
expressing lung macrophage and splenic red pulp macrophage are highlighted in medium 
and dark blue. The most likely precursor for muscle derived macrophages, Ly6c+ 
monocytes, is labeled with a red asterisk. The detailed description of all cell types is 
available upon request. (C) Expression of the other Ppar isoforms do not suggest the 
involvement of PPARδ or PPARα  (D) Expression of Pparg mRNA in day 1 WT and 
day 2 WT or Ppargfl/fl Lyz2-cre CD45+ cells and in (E) day 2 sorted Ly6c+ and Ly6c- 
MΦs isolated from CTX injured muscle. n=3 for day 1 WT CD45+ and n=5 or 4 for day 2 
WT or Ppargfl/fl Lyz2-cre CD45+ cells. n=5 and 5 for day 2 Ly6c+ or Ly6c- macrophages. 
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Fig S2.  related to Figure 1. Additional histological analysis of regeneration. 
Additional analysis to main Figure 1. (A) Cumulative CSA analysis of muscle section 
derived from WT or Ppargfl/fl Lyz2-cre animals at day 8 or day 21 post CTX injury. (B) 
Representative images of HE stained skeletal muscle from WT and Ppargfl/fl Lyz2-cre 
animals or post CTX induced injury (day 21) are shown. Scale bars represent 50 µm. n=5 
and 6 for the day 8 Ppargfl/fl Lyz2-cre vs. WT comparison and 5 and 5 for the day 21 
comparison. (C) IHC of desmin (red), F4/80 (green) and DAPI (blue) on muscle sections 
from full body Ppargfl/+ Sox2-cre- (controls) and Ppargfl/- Sox2-cre+ animals isolated at 
day 8 post CTX. Scale bars represent 100 µm. 
  
AFSC
SS
C
FSC
SS
C
FSC
SS
C
Day 4 Day 1 
Neutrophil
Day 2 
Ly6c-
F4/80 APC
Ly
6c
 P
E
F4/80 APC
Ly
6c
 P
E
F4/80 APC
Ly
6c
 P
E
F4/80 APC
Ly
6c
 P
E
F4/80 APC
Ly
6c
 P
E
F4/80 APC
Ly
6c
 P
E
WT
WT
Ppargfl/fl Lyz2-cre
Ly6c+ 
Ly6c-
27.4%
72.6%
62.8%
37.2%
28.1%
71.9%
59.2%
40.8%
Ly6c+ Ly6c+
20.7%
20.6%
Ppargfl/fl Lyz2-cre WT Ppargfl/fl Lyz2-cre
B DC
E GF
VARGA et al. Suppl Fig 3.
 4 
 
Fig S3. related to Figure 1. Analysis of macrophage infiltration and dynamics 
during regeneration (A) FACS gating strategy to enumerate muscle infiltrative 
neutrophils, and Ly6c+ and Ly6c- macrophages at day 1, 2 and 4 post CTX. 
Representative samples and gate frequencies are shown. (B) Total number of infiltrating 
CD45+ hematopoietic cells isolated from CTX injured muscles of WT and Ppargfl/fl Lyz2-
cre animals at day 1, day 2 and day 4. (D=day) n=8, 12 and 11 for WT animals and 8, 8 
and 7 for Ppargfl/fl Lyz2-cre mice from days 1, 2 or 4. (C) Percentage of neutrophils and 
Ly6c+ macrophages and the (D) calculated neutrophil and macrophage numbers at day 1 
in injured muscles. n= 8 for both genotypes. (E and F) Percentage of Ly6c+ and Ly6c- 
macrophages in injured muscles at day 2 and day 4. n=8 for WT and 11 for Ppargfl/fl 
Lyz2-cre samples at day 2 and n=12 and 7 for WT and Ppargfl/fl Lyz2-cre mice at day 4. 
(G) number of CD45+ cells isolated from regenerating muscles at day 6. Bar graphs show 
mean values +/- SD. n=4 for both genotypes. 
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Fig S4. related to Figure 2. Analysis of macrophage derived effects on muscle 
regeneration (A) Experimental strategy to measure in vitro phagocytosis in BMDMs. 
(B) Percentage of phagocytic BMDMs and the Median Fluorescent Intensity (MFI) in the 
phagocytic BMDM compartment in BMDMs derived from WT vs. Ppargfl/fl Lyz2-cre 
(upper panel) or WT BMT vs Ppargfl/+ Sox-cre BMT animals (Bottom panel). n=4 for 
each condition or genotype. FigS4 C, D, E and F provide additional information to main 
Fig. 2. (C) The pro-differentiation effect of IL4-treated BMDM supernatants on myoblast 
fusion is independent of the myoblast clone. The experiment was carried out on 3 
independently isolated myoblast lines. (D) BMDM PPARγ does not modulate the effect 
of IFN-γ -treated BMDM supernatants on myoblast fusion. n=3 (E) FACS gating strategy 
for the sorting of macrophage subsets from CTX injured muscles (F) Schematics of the 
transcriptomic analyses of sorted muscle derived macrophage populations. 
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Fig S5.  related to Figure 2. Additional analysis of the gene expression changes in 
sorted macrophage populations  (A) RT-qPCR validation of the expression pattern of 
PPARγ-dependent genes in muscle derived sterile inflammatory macrophages. n=2, 8, 10, 
1 and 4 (for day 1 Ly6c+, day 2 Ly6c+, day 2 Ly6c-, day 4 Ly6c+ (pooled) and day 4 
Ly6c- cells) from WT and n= 5, 6, 7, 1 and 4 from Ppargfl/fl Lyz2-cre mice. (B) 
Expression of alternative macrophage markers in isolated macrophage subsets (C) 
STAT6 deficiency increases the number of necrotic/phagocytic fibers after CTX injury.  
(D) STAT6 deficiency does not impair CSA restoration after CTX injury. n= 6 or 7 for 
WT or Stat6-/- muscles. (E) Heatmap representation of the expression pattern of the genes 
that are upregulated by RSG treatment in WT Ly6c- cells at day 2. Expression pattern of 
these genes are shown in all isolated macrophage subtypes. The RSG dependent 
induction is labeled with red/blue arrows on the left side. The induction in WT untreated 
day 2 Ly6c+ vs. Ly6c- macrophages, which is reminiscent to the induction caused by 
RSG treatment, is labeled with a green arrow on the left side. Different Hist2h3 isoforms 
are labeled as Histone genes. (F) Heatmap representation of lipid contents isolated from 
injured and regenerating muscles. 
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Fig S6.  related to Figure 3. Epigenomic analysis of enhancers regulated by PPARγ . 
Additional supportive information to main Fig. 3. (A) Identification of the active, PPARγ 
-regulated enhancer around the Angptl4 locus. Red vertical line labels the relevant 
enhancer. (B) Enhancer selection scheme for identifying active enhancers around the 
Gdf3 locus.  
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Fig S7.  related to Figures 6 and 7. GDF3 and muscle regeneration. Fig. S7A and B 
provides additional analysis to main Fig. 6 C and D. (A) Effect of GDF3 on the fusion of 
primary myoblasts in an in vitro myoblast assay optimized for measurement of the 
myoblasts fusion step. Representative images (left panel) and fusion indexes (+/- SEM) 
(right panel) are shown. n=3. (B) Lack of induction in myogenin protein expression 
detected by IHC in differentiating myoblasts in the presence of GDF3 (Mean values +/-
SEM). n=3. Fig. S7C provides additional data to main Fig. 7F.  (C) List of members of 
the TGF-β superfamily signaling system that are not expressed in muscle derived 
macrophages.  
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SUPPLEMENTAL TABLE LEGENDS 
 
Table S1.  related to Figure 2. Gene expression analysis of muscle infiltrative 
macrophages isolated from regenerating muscles of WT and Ppargfl/fl Lyz2-cre 
animals. Both RAW data and “per gene normalized (i.e. normalized to the median 
expression value of respective gene”) data are shown, after preliminary data processing 
of microarray data. Worksheet “Day 1 to 4 WT vs. PPARγ KO DATA” contains all data 
derived from macrophages isolated 1, 2 or 4 days post CTX treatment. Worksheet “Day 2 
WT NT vs RSG DATA” contains all data derived from day 2 post CTX mice that were 
treated +/- RSG. “COMP” worksheets contain the list of genes that are differently 
expressed when the two respective 2 macrophage populations are compared (based on a 2 
way ANOVA carried out on the whole data set). Genes with p ≤ 0.05 were considered 
significant and are listed in the comparison worksheets. 
  
Table S2. Related to Figure 7. Gene expression analysis of differentiating primary 
myoblast by RNA-Seq. Expression data from undifferentiated primary myoblasts, 
myoblasts differentiated for 1 day and myoblasts differentiated for 1 day in the presence 
of GDF3 were compared. Worksheet “MyB_all_expressed_genes_anova” lists expression 
values, p values and log2 fold change values for all genes that are differently expressed 
between any two conditions by 2 way ANOVA (p ≤ 0.05). Worksheets “Mblast vs D1” 
and “D1 vs. D1 GDF3” contain the list of genes that are differently expressed between 
the two relevant conditions. 
 
 1 
SUPPLEMENTAL MATERIALS AND METHODS 
 
Mice. Genetically modified mice and wild type (WT) C57BL/6 controls were bred 
under SPF conditions and used for experiments in accordance with Hungarian (license 
no.: 21/2011/DE MÁB) and European regulations. Experiments were conducted on 2-4 
month old male mice. Breeding of genetically modified Gdf3-/- and their control C57BL/6 
albino animals, and the experiments with them were accepted and conducted with the 
permission of Sanford Burnham Prebys Medical Discovery Institute at Lake Nona 
IACUC approval (protocol No. 2014-0107). 
Ppargfl/flLyz2-cre and wild type C57BL/6 mice were used in most experiments. 
They were generated in Ppargfl/flLyz2-cre X Ppargfl/flLyz2-cre and WT X WT crossings. 
In a separate experiment, a small cohort of Ppargfl/flLyz2-cre and littermate control 
Pparg+/+Lyz2-cre animals were generated from Ppargfl/flLyz2-cre X Ppargfl/+Lyz2-cre 
crossings. The animals from this latter cohort were CTX injected and HE stained slides 
generated 8 days post CTX injections were visually evaluated in a double blind fashion. 
This experiment detected a delay in Ppargfl/flLyz2-cre animals (vs. WT) that was 
indistinguishable from the delay seen in the Ppargfl/flLyz2-cre samples generated in the 
non-littermate crossings. 
Ppargfl/-Sox2-cre+ and littermate control Ppargfl/+Lyz2-cre- animals were generated 
in (male) Pparg+/-Sox2-Cre+ X (female) Ppargfl/flSox2-Cre- crossings. 
Gdf3-/- and littermate C57BL/6 albino controls were generated in Gdf3+/- X Gdf3+/- 
crossings. 
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Stat6-/- animals and littermate C57BL/6 controls were generated in Stat6-/- X Stat6-/- 
and C57BL/6 X C57BL/6 crossings, respectively. 
Muscle injury. Mice were anaesthetized with isoflurane and 50 µl of cardiotoxin 
(12X10-6 mol/l in PBS) (from Latoxan) was injected in the tibialis anterior (TA) muscle. 
Muscles were recovered for flow cytometry analysis at day 1, 2 or 4 post-injury or for 
muscle histology at day 8 post-injury.  Glycerol injury was performed according to 
(Heredia et al., 2013); freeze injury was performed as described in (Hardy et al., 2016); 
crush injury was performed as in (Mitchell et al., 1992). In some experiments, 300 ng 
recombinant (r) GDF3 in 50 ul PBS, was injected at day 4 post-CTX into each TA 
muscle. 
Histological analysis of muscle regeneration. Muscles were removed and snap 
frozen in nitrogen-chilled isopentane (–160°C). 8 µm thick cryosections were cut and  
stained with hematoxylin-eosin (HE). 
Picture capture and counting.  For each histological analysis, at least 5 slides (per 
condition) were selected where the total regernerative region within the CTX injured TA 
muscle was at least 70%.  For each TA, myofibers in at least 3 fields randomly chosen in 
the entire injured area were counted and measured. HE muscle sections for the day 0, day 
8 and day 21 Ppargfl/flLyz2-cre vs. WT comparisons were recorded with a Nikon E800 
microscope at 20X magnification connected to a QIMAGING camera. Cross-sectional 
area (CSA) measurement of these samples was carried out using Metamorph software 
and the CSAs are reported in arbitrary units. HE muscle sections for the day 16 and 20  
Gdf3-/- BMT vs. WT BMT and for the day 22 Ppargfl/-Sox2-cre BMT vs. WT BMT 
samples, the day 8 Stat6-/- and the Ppargfl/flLyz2-cre + recombinant GDF3 injected 
 3 
samples, were scanned with Mirax digital slide scanner and the CSA was measured with 
Panoramic Viewer software. The CSAs for these latter samples are reported in µm. 
Quantitative analysis of necrotic and/or phagocytic vs. centrally nucleated myofibers was 
performed using the Image J software and was expressed as a percentage of the total 
number of myofibers. Necrotic myofibers were defined as pink pale patchy fibers and 
phagocyted myofibers were defined as pink pale fibers, which are invaded by basophil 
single cells (macrophages). 
 Immunofluorescent detection of muscle regeneration in day 8 CTX injected 
muscle: Tissue sections were fixed and permeabilized in ice cold acetone for 5 min and 
blocked for 30 minutes at 20 °C (room temperature) in PBS containing 2 % bovine serum 
albumin (BSA). Tissues were stained for 1 h at room temperature using a primary 
antibody diluted in 2 % BSA. The primary antibodies used for immunofluorescence are 
listed in Supplementary Table 1. In all cases, the primary antibody was detected using 
secondary antibodies conjugated to FITC  (JIR 712-095-153) or Cy3 JIR (711-165-152). 
The nuclei were counter stained with 0.1-1 µg/ml Hoechst. Fluorescent microscopy was 
performed using Carl Zeiss Axio Imager Z2 microscope equipped with lasers at 488, 568 
and 633 nm. Figures were analyzed and assembled using Fiji and Illustrator CS5 
(Adobe). 
List of primary antibodies used in immunofluorescence:  
 
            
     
 
Antibody Dilution Source 
Rabbit anti-Desmin 1/200 Abcam (ab32362) 
Rat anti-F4/80 1/400  Abcam (ab664) 
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 Macrophage cell culture for conditioned medium generation. Macrophages 
were obtained from bone marrow (BM) precursor cells. Briefly, total BM was obtained 
from mice by flushing femurs and tibiae bone marrow with DMEM. Cells were cultured 
in DMEM medium containing 20% FBS and 30% conditioned medium of L929 cell line 
(enriched in CSF-1) for 7 days. Macrophages were seeded (at 50000 cell/cm2 for all 
experiments) and were activated with IFN-γ (50 ng/ml) and IL4 (10 ng/ml) to obtain M1 
and M2 macrophages, respectively, in DMEM containing 10% FBS medium for 3 days. 
After washing steps, DMEM serum-free medium was added for 24 h, recovered and 
centrifugated to obtain macrophage-conditioned medium.  
 Myogenic precursor cell (MPC) culture. Murine MPCs were obtained from TA 
muscle and cultured using standard conditions in DMEM/ F12 (Gibco Life Technologies) 
containing 20% FBS and 2% Ultroser G (Pall Inc). Briefly, TA muscles of young mice 
were opened and cleared of nerves/blood vessels/fascia etc. Muscle preparations were 
lightly digested with collagenase and the resulting cells were plated then serially 
expanded. For proliferation studies, MPCs were seeded at 10000 cell/cm2 on Matrigel 
(1/10) and incubated for 1 day with macrophage-conditioned medium + 2.5% FBS or 
with 2.5% FBS medium containing GDF3 mouse recombinant protein (300 ng/ml; R&D 
958-G3-010). Cells were then incubated with anti-ki67 antibodies (15580 Abcam), which 
were subsequently visualized using cy3-conjugated secondary antibodies (Jackson 
Immunoresearch Inc). For differentiation studies, MPCs were seeded at 30000 cell/cm2 
on Matrigel (1/10) and incubated for 3 days with macrophage-conditioned medium 
containing 2% horse serum or with 2% horse serum medium containing GDF3 mouse 
recombinant protein (300 ng/ml; R&D). Cells were then incubated with anti-desmin 
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antibodies (32362 Abcam), in combination with a cy3-conjugated secondary antibody 
(Jackson Immunoresearch Inc). 
 In vitro effects of GDF3 on myogenesis: Myogenic cell differentiation (i.e. 
myoblast commitment into differentiated myocytes) was evaluated as described earlier 
(Saclier et al., 2013). Cells were seeded at 30000 cells/cm2 in the presence of the absence 
of GDF3 (100 ng/ml) for 24h. Myogenin immunostaining (sc-12732, 1/20) was 
performed and the number of myogenin-positive nuclei was assessed for myogenic 
differentiation. 
Myogenic cell fusion was evaluated as described earlier (Saclier et al., 2013). Cells were 
first seeded at 5000 cells/cm2 in differentiation medium and the differentiating myocytes 
were lifted and re-seeded at 75000 cells/cm2 in the presence of the absence of GDF3 
(100 ng/ml) for 3 days. The number of nuclei in the myotubes was evaluated after desmin 
(AB32362 1/200) immunostaining and assessed for myogenic cell fusion. 
P-SMAD2 signaling was evaluated in myogenic cell that have been cultured in the 
presence of the absence of GDF3 (100 ng/ml) for 6h. pSMAD2 (AB3849 
Millipore,1/500) immunostaining was performed and the number of positive cells was 
counted. 
 Phagocytosis assay: BMDM cells were generated as described earlier in this 
section. BMDMs were harvested with trypsin and careful scraping, washed twice in PBS 
and then stained with the lipophilic fluorescent dye CellVue (Sigma) according to the 
manufacturer’s recommendation. Stained BMDMs were replated and let to recuperate for 
one day in DMEM medium. C2C12 cells were cultured in DMEM containing 10% FBS. 
Cells were harvested, washed and stained with the lipophilic fluorescent dye PKH67 
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(Sigma). Stained C2C12 cells were washed extensively and then heat killed at 55°C for 
60 min. Heat killed C2C12 cells were added to BMDM cultures at 2:1 ratio and 
phagocytosis was commence at 37°C or 4°C (controls). Cells were harvested by scraping 
after 1 h and fluorescent intensity was detected with a FACScalibur instrument. 
Isolation of macrophages from muscle: Fascia of the TA was removed. Muscles 
were dissociated in RPMI containing 0.2% collagenase B (Roche Diagnostics GmbH) at 
37°C for 1 hour and filtered through a 100 µm and a 40 µm filter. CD45+ cells were 
isolated using magnetic sorting (Miltenyi Biotec). For cell sorting, macrophages were 
treated with Fcγ receptor blocking antibodies and with 10% normal rat serum: normal 
mouse serum 1:1 mix, then stained with a combination of PE-conjugated anti-Ly6c 
antibody (HK1.4, eBioscience) and APC-conjugated F4/80 antibody (BM8, eBioscience). 
Ly6c+ F4/80low macrophages, Ly6c- F4/80+ macrophages and Ly6cmid F4/80- neutrophils 
were sorted. In each experiment, both genotypes were processed in parallel to minimize 
experimental variation. Cells were analyzed and/or sorted with a BD FACSAria III sorter.  
Isolation of macrophages and FAP cells from CTX injured muscles: CTX 
injured TA muscles were dissected and fat/nerves/fascias/tendons were discarded. 
Muscles were pulped and treated with a collagenase/dispase cocktail. CD45+F4/80+ 
macrophages and CD45-CD31-Sca1+PDGFRA(CD140)+ FAPs were sorted for RNA 
isolation.  
RNA isolation from sorted MFs. MF subsets were sorted from day 1, 2 and 4 
post-injury muscles with a FACSAria III sorter and total RNA was isolated with TRIZOL 
reagent according to the manufacturer’s recommendation. 20 ug glycogen (Ambion) was 
added as a carrier for RNA precipitation.  
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 Microarray analysis of muscle macrophages: Global expression pattern was 
analyzed on Affymetrix GeneChip Mouse Gene 1.0 ST arrays. Ambion WT Expression 
Kit (Life Technologies, Hungary) and GeneChip WT Terminal Labeling and Control Kit 
(Affymetrix) were used for amplifying and labeling 150 ng of total RNA. Samples (n=3, 
4 or 5) were hybridized at 45 ºC for 16 h and then standard washing protocol was 
performed using Affymetrix GeneChip Fluidics Station 450. The arrays were scanned on 
GeneChip Scanner 7G (Affymetrix). Microarray data (data acess: GSE44057) were 
analyzed with GeneSpring 12 GX software (Agilent BioTechnologies). Affymetrix CEL 
files were normalized with Robust Multichip Analysis (RMA) algorithm and median 
normalization. 
The microarray data are publicly available (Data access: GSE71155). 
 Expression data processing and analysis: Data quality control and analysis was 
carried out following the recommendations put forward in the Imgen website 
(http://www.immgen.org/Protocols/ImmGen%20QC%20Documentation_ALL-
DataGeneration_0612.pdf). 
Data were loaded into the Genespring GX software and RMA summarization was carried 
out. Next, a set of filtering steps was applied to the dataset. Briefly, data distribution curve 
was generated and the lowest 5% of the entities with detectable signals were filtered out 
as not expressed. Duplicate entities, not/poorly annotated transcripts and transcripts 
reporting inconsistent expression values were also discarded. Further analysis was carried 
out on the filtered dataset.  Data was analyzed either based on the RAW expression 
values or after following a “per gene” normalization (individual gene expression data 
normalized to the median of the gene).  
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Further analysis of gene expression and comparisons were made either within Genespring 
GX or using the R software package. 2-way anova tests were performed in R using 
functions aov and TukeyHSD of package MASS, Heatmaps were drawn with package 
pheatmap. Statistically significant difference was considered if p < 0.05.  
 Microarray validation by RT-qPCR: Transcript quantification was performed 
by quantitative real-time RT (reverse transcriptase) PCR (polymerase chain reaction) 
using SYBR Green assays (Apold1, Hebp1 and Plxnd1) or PrimeTime assays from IDT 
(Gdf3 and Pparg). Primer sequences and Taqman probes or PrimeTime assay IDs used in 
transcript quantification are available upon request. RT-qPCR results were analyzed with 
the standard delta Ct method and results were normalized to the expression of Actb. 
 Identification and quantification of lipid mediators by liquid 
chromatography-tandem mass spectrometry. Tibialis anterior muscles collected after 
CTX-induced injury were minced in ice-cold methanol and stored at -80°C. Internal 
deuterium-labeled standards, including d8-5-HETE and d4-PGE2, were then added to 
assess extraction recovery and quantification.  Solid phase extraction and LC-MS/MS 
analysis were carried out essentially as described in (Colas et al., 2014). Briefly, lipid 
mediators were extracted by C18 column chromatography and methyl formate fractions 
were taken to dryness under a stream of N2 gas prior to suspension in methanol:water 
(50:50).  Samples were profiled using a high performance liquid chromatograph (HPLC, 
Shimadzu) coupled to a QTrap5500 mass spectrometer (AB Sciex).  The instrument was 
operated in negative ionization mode and lipid mediators were identified and quantified 
using multiple reaction monitoring (MRM) transitions (Colas et al., 2014) after 
normalization to extraction recovery based on internal deuterium-labeled standards and 
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external calibration curves for each mediator.  The specific MRM transitions used were: 
PGE2 (351>175), PGD2 (351>233), PGF2α (351>193), 15-HETE (319>219) and 12-
HETE (319>179). 
 Macrophage cell culture for ChIP: Macrophages were obtained from bone 
marrow (BM) precursor cells. Briefly, total BM was obtained from mice by flushing 
femurs and tibiae bone marrow with DMEM. Cells were RBC lysed with ACK solution 
and then plated on non-tissue culture grade plates then cultured in DMEM medium 
containing 20% FBS and 30% conditioned medium of L929 cell line (enriched in CSF1) 
for 6 days. Macrophages were harvested from the culture plates and ChIP was carried 
out. 
ChIP (Chromatin immunoprecipitation): Cells were double crosslinked with 
0,002M DSG (Sigma) for 30 minutes and then with 1% formaldehyde (Sigma) for 10 
minutes. Nuclei were isolated with ChIP Lysis Buffer (1% Triton x-100, 0.1% SDS, 150 
mM NaCl, 1mM EDTA, and 20 mM Tris, pH 8.0) then chromatin were sonicated (also in 
ChIP Lysis Buffer) with Diagenode Bioruptor to generate 200-1000 bp fragments. 
Chromatin was diluted in ChIP Lysis buffer and immunoprecipitated with antibodies 
against pre-immune IgG (Millipore, 12-370), (pan) RXR (sc-774 Santa Cruz 
Biotechnology) and PPAR gamma (Perseus #PP-A3409A). Chromatin antibody 
complexes were precipitated with Protein A coated paramagnetic beads (Life 
Technologies). Chromatin antibody complexes were washed on the beads once in IP 
Wash Buffer 1 (1% Triton, 0.1% SDS, 150 mM NaCl, 1 mM EDTA, 20 mM Tris, pH 
8.0, and 0.1% NaDOC), twice in IP Wash Buffer 2 (1% Triton, 0.1% SDS, 500 mM 
NaCl, 1 mM EDTA, 20 mM Tris, pH 8.0, and 0.1% NaDOC) and once in IP Wash Buffer 
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3 (0.25 M LiCl, 0.5% NP-40, 1mM EDTA, 20 mM Tris, pH 8.0, 0.5% NaDOC) and IP 
Wash Buffer 4 (10 mM EDTA and 200 mM Tris, pH8.0). DNA fragments were then 
eluted and column purified (Qiagen, MinElute). DNA was applied for QPCR analysis. 
QPCR results were analyzed with the standard delta Ct method and results were 
normalized to input signals. 
Bioinformatic analysis of the active enhancers around the Gdf3 and Angptl4 
locus: Primary analysis of the raw sequence reads has been carried out using our ChIP-
seq analysis command line pipeline. Alignment to the mm9 assembly of the mouse 
genome was done by the Burrows–Wheeler Alignment (BWA) tool. Genome coverage 
(bedgraph) files were generated by makeTagDirectory and makeUCSCfile.pl (HOMER) 
and were used for visualization with IGV2. Putative DR1 elements (reaching score 9) 
were determined by annotatePeaks.pl (HOMER) using the RXR and PPARg motif 
matrices of HOMER. The following datasets were used for the identification of active 
enhancers: 
Sample name 
SRA 
 identifier 
GEO  
identifier Cell/tissue type 
Sample  
type Antibody 
BMDM_PU.1 SRX651749 - bone marrow derived macrophage ChIP-seq PU.1 
BMDM_RXR SRX651739 - bone marrow derived macrophage ChIP-seq RXR 
mac_PPARg SRX019134 GSM532739 peritoneal macrophage ChIP-seq PPARg 
eWAT_PPARg SRX193440 GSM1018066 epididymal white adipose tissue ChIP-seq PPARg 
iWAT_PPARg SRX193441 GSM1018067 inguinal white adipose tissue ChIP-seq PPARg 
BAT_PPARg SRX193442 GSM1018068 brown adipose tissue ChIP-seq PPARg 
BMDM_CTCF SRX651751 - bone marrow derived macrophage ChIP-seq CTCF 
BMDM_RAD21 - - bone marrow derived macrophage ChIP-seq RAD21 
BMDM_H3K4me3 SRX651747 - bone marrow derived macrophage ChIP-seq H3K4me3 
BMDM_GRO-seq SRX651735 - bone marrow derived macrophage GRO-seq - 
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 Western Blotting: GDF3 protein expression was measured using Western Blot 
analysis. The Tibialis anterior (TA) was removed from mice injected intramuscularly 
with cardiotoxin (CTX) at experimental time points and homogenized in RIPA buffer. 
CD45+/- cell populations were isolated from whole TA muscle using MACS Micro 
Magnetic Bead Separation system (Bergisch Gladbach, Germany). Cell populations were 
collected and lysed in RIPA buffer. Protein concentrations were determined by Qubit 2.0 
Fluorometer Protein Assay (Life Technologies, Carlsbad, CA). Protein samples were 
prepared for SDS-PAGE with 2X Laemmli Sample Buffer (Bio-Rad, Hercules, CA) at a 
1 mg/ml concentration. SDS-PAGE was completed using 4-20% Mini Protean TGX gels 
(Bio-Rad, Hercules, CA) at 110 volts for 1 hour. The SDS-PAGE gel was then 
transferred onto PVDF membrane (Thermo Fisher, Waltham, MA) at 0.35 amps for 1-2 
hours at 4°C. Membranes were blocked in 5% BSA in TBS-T at room temperature for >1 
hour. GDF3 was targeted using rabbit monoclonal Anti-GDF3 primary antibody 
(ab109617, Abcam, Cambridge, MA) at 1:1,000 dilution in 5% BSA/TBS-T overnight at 
4°C. Anti-GAPDH mouse monoclonal primary antibody (AM4300, Ambion, Carlsbad, 
CA) was used as a protein loading control at 1:10,000 – 1:20,000 dilution in 5% 
BSA+TBST overnight at 4°C. Membranes were washed 3X with TBS-T for 5 minutes 
each for a total of 15 minutes. Goat Anti-Rabbit HRP secondary antibody was used for 
the detection of GDF3 at 1:10,000 dilution in 5%BSA+TBS-T at room temperature for 1 
hour. Anti-Mouse HRP secondary (Cell Signaling, 7076S) and Donkey Anti-Mouse 
Alexa Fluor 680 secondary (ab175774) antibodies were used for the detection of GAPDH 
at 1:40,000 dilution at room temperature for 1 hour. Membranes were washed 3X with 
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TBS-T for 5 minutes each for a total of 15 minutes, followed by 2 washes in TBS for 5 
minutes. Super Signal West Pico Kit allowed for ECL visualization of the blot on Hyblot 
CL Film (Denville, E3018). 
 RNA sequencing (RNA-Seq) library preparation for myoblast gene 
expression analysis: Myoblast cells were plated at 30.000/cm2. After cell adhesion, 
medium was replace to differentiation medium (DMEM/F12 containing 2% horse 
serum). After overnight differentiation, 150 ng/ml GDF3 was added to selected wells. 
Cells were harvested in trizol in 24h and RNA was isolated following the suppliers’s 
recommendations. cDNA library for RNA-Seq was generated from 1µg total RNA using 
TruSeq RNA Sample Preparation Kit (Illumina, San Diego, CA, USA) according to the 
manufacturer’s protocol. Briefly, poly-A tailed RNAs were purified by oligodT 
conjugated magnetic beads and fragmented on 94 C degree for 8 minutes, then 1st strand 
cDNA was transcribed using random primers and SuperScript II reverse transcriptase 
(Lifetechnologies, Carlsbad, CA, USA). Following this step, second strand cDNA were 
synthesized and then double stranded cDNA molecules were end repaired resulting blunt 
ends. The 3’ ends of the dscDNA molecules were adenylated then Illumina TruSeq index 
adapters were ligated. After adapter ligation step, enrichment PCR was performed to 
amplify the adapter-ligated cDNA fragments. Fragment size distribution and molarity of 
the libraries were checked on Agilent BioAnalyzer DNA1000 chip (Agilent 
Technologies, Santa Clara, CA, USA). 
10 pM of denatured libraries were used for cluster generation on cBot instrument, 
then single read 50bp sequencing run was performed on Illumina HiScan SQ instrument 
(Illumina, San Diego, CA, USA).  
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The RNA-Seq data are publicly accessible (data access: 
PRJNA290560/SRR2136645). 
 RNA-seq bioinformatics analysis: The TopHat-Cufflinks toolkit was used for 
mapping spliced reads, making transcript assemblies, getting and sorting gene expression 
data. Genes with RPKM>=1 (at least in one sample) were considered to be expressed.  2-
way ANOVA tests were performed in R using functions aov and TukeyHSD of package 
MASS, Heatmaps were drawn with package pheatmap. 
General statistical analyses. All experiments were performed using at least three 
different samples. Student’s t-tests and 2 way ANOVA analyses were performed and 
P<0.05 was considered significant (P<0.05=*, P<0.01=**, P<0.001=***). Mean and SD 
values, or mean and SEM values are shown in graphs. 
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